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ABSTRACT
Cancer chemotherapy sensitizers hold the key
to maximizing the potential of standard anti-
cancer treatments. We have a long-standing
interest in developing and validating inhibitors
of the DNA repair enzyme tyrosyl-DNA phos-
phodiesterase 1 (TDP1) as chemosensitizers for
topoisomerase I poisons such as topotecan.
Herein, by using thieno[2,3-b]pyridines, a class
of TDP1 inhibitors, we showed that the inhibi-
tion of TDP1 can restore sensitivity to topote-
can, results that are supported by TDP1
knockout cell experiments using CRISPR/Cas9.
However, we also found that the restored sen-
sitivity towards topoisomerase I inhibitors is
likely regulated by multiple complementary
DNA repair pathways. Our results showed that
one of these pathways is likely modulated by
PARP1, although it is also possible that other
redundant and partially overlapping pathways
may be involved in the DNA repair process. Our
work thus raises the prospect of targeting
Euphemia Leung and Jinal Patel contributed equally to
this work.
Supplementary Information The online version
contains supplementary material available at https://
doi.org/10.1007/s40487-021-00158-0.
E. Leung (&)  P. Tomek  B. C. Baguley 
W. A. Denny
Auckland Cancer Society Research Centre, School of
Medical Sciences, The University of Auckland,
Private Bag 92019, Victoria Street West, Auckland
1142, New Zealand
e-mail: e.leung@auckland.ac.nz
E. Leung  J. A. Hollywood  R. J. Langley 
N. A. Helsby
Department of Molecular Medicine and Pathology,
School of Medical Sciences, The University of
Auckland, Private Bag 92019, Victoria Street West,
Auckland 1142, New Zealand
E. Leung  R. J. Langley  C. J. Squire 
I. K. H. Leung (&)
Maurice Wilkins Centre for Molecular Biodiscovery,
The University of Auckland, Private Bag 92019,
Victoria Street West, Auckland 1142, New Zealand
J. Patel  A. Zafar  D. Barker  L. I. Pilkington 
M. van Rensburg  J. Reynisson (&)  I. K. H. Leung
School of Chemical Sciences, The University of
Auckland, Private Bag 92019, Victoria Street West,
Auckland 1142, New Zealand
D. Barker
The MacDiarmid Institute for Advanced Materials
and Nanotechnology, Victoria University of
Wellington, PO Box 600, Wellington 6140, New
Zealand
C. J. Squire
School of Biological Sciences, The University of
Auckland, Private Bag 92019, Victoria Street West,
Auckland 1142, New Zealand
J. Reynisson
School of Pharmacy and Bioengineering, Keele




multiple DNA repair pathways to increase the
sensitivity to topoisomerase I inhibitors.
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Key Summary Points
Why carry out this study?
Side effects and the development of
chemoresistance are unresolved
challenges in cancer chemotherapy.
Chemosensitizers may help solve these
issues by making cancer cells more
vulnerable to conventional chemotherapy
drugs.
Our work aims to validate the DNA repair
enzyme tyrosyl-DNA phosphodiesterase 1
(TDP1) as an inhibition target for the
development of chemosensitizers for
camptothecin-based chemotherapy drugs
such as topotecan.
What was learned from the study?
Inhibition of TDP1 may restore sensitivity
to topotecan.
TDP1 inhibitors also induced a
potentiation effect in TDP1 knockout
cells, indicating that multiple
complementary DNA repair pathways
may exist to repair the DNA damage
caused by topotecan.
Our results highlight the prospect of
targeting multiple DNA repair pathways
to increase the sensitivity to
topoisomerase I inhibitors.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go tohttps://doi.org/10.6084/m9.
figshare.14725317.
INTRODUCTION
Although chemotherapy is now routinely
applied to treat cancer patients, the unpleasant
(and sometimes severe) side effects and the
eventual development of chemoresistance
remain unresolved challenges. In order to mit-
igate these issues, the use of chemosensitizers to
enhance the efficacy of chemotherapy has been
a focus of intense research in the last two dec-
ades [1, 2]. Chemosensitizers make cancer cells
more vulnerable to conventional chemotherapy
drugs, allowing lower dosages to be used [1, 2].
Hence, chemosensitizers hold the potential to
delay or reverse chemoresistance, reduce
dosage-related toxicity and minimize side
effects.
Topotecan and irinotecan are among the
Food and Drug Administration (FDA)-approved
chemotherapy drugs that are structurally based
on camptothecins [3–5]. Camptothecins are
pentacyclic quinoline alkaloids that target DNA
topoisomerase I, a DNA-cleaving enzyme that
plays a key role in relaxing tangled DNA during
its replication and transcription [6, 7]. Camp-
tothecins inhibit topoisomerase I by trapping
the covalent topoisomerase I-DNA complex,
which in turn interferes with the cellular
replicative and transcriptional machinery [8, 9].
This causes DNA damage and potent cytotoxi-
city, which is utilized to kill rapidly dividing
cancer cells. However, the cytotoxicity of
camptothecins is limited by intrinsic cancer cell
resistance, which is thought to be mediated by
DNA repair pathways [10–12]. One of these
DNA pathways is modulated by the enzyme
tyrosyl-DNA phosphodiesterase 1 (TDP1)
[13–15]. TDP1 releases stalled topoisomerase
I-DNA cleavage complexes by catalyzing the
hydrolysis of the phosphodiester bond between
the catalytic tyrosine residue of topoisomerase I
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and the phosphate group of DNA [13–15]. The
activity of TDP1 and topoisomerase I in tumor
cells is positively correlated [16]. There is evi-
dence that TDP1 expression may lessen the
cytotoxicity of camptothecin-based drugs [17].
Preclinical data have also shown that the level
of TDP1 activity may influence cellular sensi-
tivity to camptothecin-based drugs and other
topoisomerase I inhibitors [18, 19].
Our laboratories have a long-standing inter-
est in the development and validation of sen-
sitizers for camptothecin-based chemotherapy
drugs [20–38]. Specifically, our recent work
indicated that TDP1 inhibitors may potentiate
topotecan both in vitro and in vivo [31].
Although this study provides an impetus for the
development of selective TDP1 inhibitors as
camptothecin sensitizers, the presence of mul-
tiple DNA repair pathways and enzymes other
than TDP1 may present an obstacle to this drug
development prospect [39–43]. Thus, it is
important to illuminate the association
between TDP1 activity and camptothecin sen-
sitivity. Our previous work showed that com-
pounds containing the thieno[2,3-b]pyridine
scaffold are inhibitors of TDP1 [35, 38], and
thus represent excellent model compounds for
the investigation. We therefore set out to study
the modulation of TDP1 activity with




Unless otherwise stated, all chemicals were
obtained from Sigma-Aldrich, Merck, Life
Technologies, Bio-Rad, Abcam and AK Scien-
tific. Topotecan and olaparib were purchased
from Sigma-Aldrich.
Cell Culture
Culture conditions have been described in
detail previously [44, 45]; Hs578T, BT549, MDA-
MB-231, SKBR3, MCF7, T47D, BT474, MDA-MB-
453, MDA-MB-436, A172, SUM149T, HCF116,
MiaPaCa, PANC1, A549, HeLa and H460 cancer
cell lines were purchased from the American
Type Culture Collection (ATCC). SUM149PT
and SUM150PT were grown in Ham’s F-12 with
5% fetal calf serum (FCS) supplemented with
5 lg/mL insulin, 1 lg/mL hydrocortisone,
10 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES; pH 7.4) and penicillin/
streptomycin (100 U/mL and 100 lg/mL,
respectively). All other cells were grown in a-
MEM containing 5% fetal bovine serum (FBS),
insulin/transferrin/selenium supplement,
added according to the manufacturer’s instruc-
tions (Roche), and penicillin/streptomycin (100
U/mL and 100 lg/mL, respectively). Ethics
committee approval was not required for the
handling of commercial cell lines.
Cell Proliferation Assay
As described in detail previously [44], prolifera-
tion was measured using a thymidine incorpo-
ration assay. A total of 3000 cells were seeded in
96-well plates in the presence of varying con-
centrations of inhibitors for 3 days. 3H-thymi-
dine was added to each well and incubated for
6 h; the cells were harvested on glass fiber filters
using an automated Tomtec harvester. Filters
were incubated with Betaplate Scint and thy-
midine incorporation measured in a TriLux/
Betaplate counter. The effects of the inhibitors
were determined relative to the incorporation
of 3H-thymidine into DNA of control (non-
drug-treated) cells.
Guide Ribonucleic Acid (gRNA) Design
and Cloning
Optimal gRNA [46] with forward and reverse
oligos 50-CACC GACATCTCTGCTCCCAATGA-
3’ and 50-AAAC TCATTGGGAGCAGAGATGTC-
30 were ligated and cloned into the pSpCas9
(BB)-2A-GFP (PX458) vector by Golden Gate
cloning [47]; pSpCas9(BB)-2A-GFP (PX458) was
a gift from Feng Zhang (Addgene plasmid #
48138; http://n2t.net/addgene:48138;
RRID:Addgene_48138). Cells were transfected
by Lipofectamine 3000, and GFP-positive cells
were isolated 48 h later by flow cytometric
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sorting and seeded as single cells. Knockout
clones were confirmed by PCR amplification of
the targeted exon followed by sequence analysis
(see Supporting Information, Figure S1) to
confirm disruption of coding sequences at the
targeted site. Cells are referred to as MCF7
TDP1_KO_2.8 and H460 TDP1_KO_1.3. Ethics
committee approval was not required for the
mutation of the cell lines.
Western Blotting
As described in detail previously [44], breast
cancer cell lines were grown to log-phase,
washed twice with ice-cold PBS, and lysed in
SDS lysis buffer according to the manufacturer’s
protocol (Cell Signaling Technology, Danvers,
MA, USA). Protein concentration was quantified
using the bicinchoninic acid reagent (Sigma).
Cell lysates containing 25 lg of protein were
separated by SDS–polyacrylamide gel elec-
trophoresis (PAGE) and transferred to PVDF
membranes (Millipore). Membranes were sub-
jected to immunoblotting with antibodies
against TDP1 (Abcam AB4166), PARP1 (Cell
Signaling Technology #9542), and tubulin
(Sigma). Bound antibody was visualized using
the Pierce ECL Western Blotting Substrate
(Thermo Fisher Scientific) and chemilumines-
cence detection by the ChemiDoc imaging sys-
tem (Bio-Rad).
Flow Cytometric Analysis
Cells (5 9 105 cells for MCF7 or 5 9 105 cells for
H460 per well) were grown in 6-well plates
overnight. After 24 h, cells were incubated for
2 h with inhibitors. The concentration used for
DJ009 was 5 lM, and the topotecan concentra-
tion was 0.5 lM for MCF7 or 1 lM for H460.
Cells were harvested, washed and resuspended
in 1 mL of blocking buffer (1% FCS/PBS), and
incubated with antibody to c-H2AX (phospho-
rylated Ser139) (Millipore, USA) in blocking
buffer (1:500 dilution) at room temperature for
2 h. Cells were washed, incubated with goat
anti-mouse Alex 488 Fab fragment secondary
antibody (Invitrogen) (1:400 in blocking buffer
for 1 h, at room temperature; dark), washed and
resuspended in 1 mL of blocking buffer con-
taining RNase (1 lg/mL) and propidium iodide
(PI) (10 lg/mL) for 30 min at room temperature.
Cells were analyzed in a Becton Dickinson BD
Accuri C6 flow cytometer.
Data analysis
The Bliss additivism model [48] was used to
classify the effect of combining topotecan and
other inhibitors as additive, synergistic, or
antagonistic. A theoretical curve was calculated
for combined inhibition using the equation
Ebliss ¼ EA þ EB  EA  EB, where EA and EB
are the fractional inhibitions obtained by drug
A alone and drug B alone at specific concen-
trations. Ebliss is the fractional inhibition that
would be expected if the combination of the
two drugs was exactly additive. The differences
(Bliss) in the experimentally measured frac-
tional inhibition (Expt) and Ebliss are defined as
synergism (Expt\ Ebliss), additivity (Expt = Ebliss),
and antagonism (Expt[Ebliss). Bliss = 0 would
indicate the combination is additive; Bliss[0
would indicate the percentage increase in
maximal inhibition above additivity (synergy);
and Bliss\ 0 would indicate the percentage
decrease in maximal inhibition below additivity
(antagonism).
TDP1 Biosensor Assay
The recombinant TDP1 was purified as descri-
bed below. The TDP1-biosensor 50-(5,6 FAM-aac
gtc agg gtc ttc c-BHQ1)-30 was purchased from
Integrated DNA Technologies; 5,6 FAM is fluo-
rophore 5(6)-carboxyfluorescein, and BHQ1 is
fluorescence quencher Black Hole Quencher 1.
As described in detail previously [31], the TDP1-
biosensor, with a final concentration of 50 nM,
was incubated in a volume of 200 lL containing
a TDP1 buffer (50 mM Tris–HCl pH 8.0, 50 mM
NaCl, 7 mM b-mercaptoethanol) supplemented
with a purified 3 nM TDP1. The reaction mix-
tures were incubated at a constant temperature
of 248C in an EnSpire 2300 Multimode Plate
Reader (PerkinElmer, Singapore) to measure
fluorescence every 1 min (Ex485/Em520 nm).
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The relative TDP1 activity was measured at
7 min compared to that of DMSO control wells.
Molecular Modeling
The compounds were docked against the crystal
structure of TDP1 (PDB ID: 6DIE, resolution
1.78 Å) [49] which was obtained from the Pro-
tein Data Bank (PDB) [50, 51]. The Scigress
version FJ 2.6 program [52] was used to prepare
the crystal structure for docking, i.e., the
hydrogen atoms were added, the co-crystallised
ligand benzene-1,2,4-tricarboxylic acid was
removed as well as crystallographic water
molecules except HOH 814, 821 and 1078. The
water molecules were set on toggle—bound or
displaced by the ligand during docking, and
spin—automatic optimization of the orienta-
tion of the hydrogen atoms. The Scigress soft-
ware suite was also used to build the inhibitors,
and the MM2 force field [53] was applied to
identify the global minimum using the CON-
FLEX method [54] followed by structural opti-
mization. The docking center was defined as the
position of a carbon on the ring of the co-crys-
tallized benzene-1,2,4-tricarboxylic acid
(x = -6.052, y = -14.428, z = 33.998) with
10 Å radius. Fifty docking runs were allowed for
each ligand with default search efficiency
(100%). The basic amino acids lysine and argi-
nine were defined as protonated. Furthermore,
aspartic and glutamic acids were assumed to be
deprotonated. The GoldScore (GS) [55] and
ChemScore (CS) [56, 57] ChemPLP (Piecewise
Linear Potential) [58] and ASP (Astex Statistical
Potential) [59] scoring functions were imple-
mented to predict the binding modes and rela-




Synthetic DNA encoding human TDP1 (residues
149–608) [14] was cloned into pET-28a(?)
(GenScript), which was then transformed into
Escherichia coli BL21(DE3) for recombinant pro-
tein production. Protein production was
induced with 1 mM isopropyl ß-D-1-
thiogalactopyranoside (IPTG) at 28 C with
overnight incubation. TDP1 was purified using
affinity and size exclusion chromatography.
The purified protein was aliquoted and stored
at -80 C until use.
Intrinsic protein fluorescence
Fluorescence was measured using a PerkinElmer
EnSpire Multimode Reader. The TDP1 concen-
tration was 10 lM and compound concentra-
tions were 50 lM, 100 lM, 200 lM, 400 lM,
600 lM and 800 lM. The buffer was composed
of 20 mM Tris and 250 mM NaCl (pH 8). The
excitation wavelength was 280 nm and the
intrinsic fluorescence was measured at 350 nm.
Control experiments with TDP1 or compound
on its own were also conducted. Background
fluorescence arising from the compounds was
subtracted from the final spectrum. The total
volume per well was 30 lL. Dissociation con-
stants (KD) were calculated using the following
formula, which takes nonspecific binding into
account [60].
I ¼ Imax  LT½ 
KD þ LT½ 
þ NS LT½ ;
where I indicates changes in fluorescence
intensity from the titration, Imax indicates the
maximum fluorescence intensity change, [LT] is
the titration ligand concentration, and Ns is the
nonspecific term. Nonlinear curve fitting was
conducted using SigmaPlot 13.0 (Systat Soft-
ware, San Jose, CA, USA). Experiments were




Crystallography screening was performed in
crystallization plates in a 96-well format. The
highly purified human TDP1148-608 was buffer-
exchanged into a buffer containing 50 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) and 50 mM NaCl at pH 7.8 and was
then concentrated to 6.5 mg/mL. After 6–8 days
of incubation at 18 C, the formation of large
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needle-shaped crystals was observed in the fine-
screened liquid containing 200 mM ammonium
chloride, 100 mM HEPES, pH 7 and 20% PEG
6000. The crystals were supplemented with 20%
glycerol and then flash-frozen in liquid nitrogen
for data collection.
Data Collection and Processing
The data for TDP1148-608 were collected remo-
tely at the School of Biological Sciences, The
University of Auckland, using the Australian
Synchrotron MX2 beamline. The data were
collected using MX2 beamline with the help of
Blu-Ice software with a resolution of 2.13 Å [61].
The TDP1149-608 data were indexed and inte-
grated using the autoprocessing software XDS
[62]. The data were scaled using the AIMLESS
software package [63].
Crystallographic Refinement
The structure was solved by molecular replace-
ment using the PHASER MR program [64] using
the available published crystal structure from
the PDB [65]. The structure was solved in
P212121, which is expected as per published
PDB (1JY1) (detail numbers are described in
Supporting Information, Table S1). The final
structure was then refined using the REFMAC
software package [66], and coordinates and
electron density were observed using COOT
modeling software [67]. The water molecules
were identified by their spherical electron den-
sity and appropriate hydrogen bond geometry
with the surrounding structure. The preliminary
coordinates were visualized, and figures were
produced using Pymol [68].
RESULTS
As our initial work with thieno[2,3-b]pyridines
and TDP1 was conducted with a relatively small
library [35, 38], we first carried out in vitro
studies to validate thieno[2,3-b]pyridines as
inhibitors of TDP1. One of our laboratories has
synthesized and acquired[100 thieno[2,3-
b]pyridines derivatives [35, 38, 69–77]. By using
this extensive library, we screened for inhibition
of TDP1 activity using a fluorescence-based
inhibition assay with a synthetic oligonu-
cleotide biosensor as substrate [78]. At 25 lM
ligand concentration, 28 (22%) out of the 128
derivatives showed[50% TDP1 inhibition (see
Supporting Information, Figure S2). For the
purpose of this study, three of the 28 com-
pounds were chosen for further evaluations
(DJ009, DJ016 and DJ282; Fig. 1). They were
chosen because of their strong inhibitory effect
in the biosensor assay and low antiproliferative
activity at 500 nM. Binding studies using
intrinsic fluorescence spectroscopy showed that
these three compounds bind to TDP1 with
affinity in the micromolar range (see Support-
ing Information, Figures S3–S5). In agreement
with previous studies [35, 38], molecular mod-
eling showed that these three compounds have
a plausible binding conformation in the active
site (see Supporting Information, Figures S6–S8
and Table S2). Protein X-ray crystallography was
also attempted. However, despite numerous
attempts using both the soaking and co-crys-
tallization methods, we were only able to obtain
the structure of apo-TDP1, which is almost
identical to the published TDP1 structure (see
Supporting Information Figure S9 and Table S1)
[65].
Having confirmed that thieno[2,3-b]pyridi-
nes inhibit TDP1 in vitro, we set out to examine
the synergistic effects of thieno[2,3-b]pyridines
and topotecan on the proliferation of cancer
cell lines. DJ009 was used against a panel of 16
cancer cell lines as an initial screen. These cell
lines were chosen to reflect the cancers that
topotecan is currently used to treat in the clinic,
as well as a number of other cell lines to eval-
uate whether TDP1 inhibitors could broaden
the spectrum of cancers that could be targeted
Fig. 1 Structures of DJ009, DJ016 and DJ282
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by topotecan. The IC50 (concentration that
reduces cell proliferation by 50%) values of
topotecan alone or in combination with DJ009
were determined using thymidine incorpora-
tion assay after 72 h of drug exposure. Interest-
ingly, sensitivity to topotecan varied between
the cell lines. At 500 nM, DJ009 significantly
sensitized the inhibitory effect of topotecan in
the MCF7 breast cancer cell line, as well as the
lung cancer cell lines A549 and H460 (Fig. 2,
and see Supporting Information, Figure S10).
Similarly, DJ016 and DJ282 showed a synergis-
tic effect to topotecan when tested against
MCF7 and H460 cells (Fig. 2). As control, DJ009,
DJ016 or DJ282 on their own at 1 lM concen-
tration had no or little effect on the prolifera-
tion of the cancer cell lines (Fig. 2), indicating
that the inhibition observed in the combination
experiments was likely due to topotecan. To
further verify that topotecan is the compound
that reduces the observed growth, we tested for
DNA damage in H460 and MCF7 cells by mea-
suring c-phosphorylation of the histone H2AX,
which is a marker for DNA damage (see Sup-
porting Information, Figure S11) [79]. A com-
parison of flow cytometry profiles following
treatment for 2 h showed an S-phase-specific
DNA damage profile with a significant c-H2AX
increase in combination treatment with DJ009
and topotecan compared with topotecan alone
(see Supporting Information, Figure S11). As
control, DJ009 induced no DNA damage
response (see Supporting Information, Fig-
ure S11). This result showed that the growth
inhibitory effect and increased DNA damage are
likely due to impaired DNA repair mechanisms
in H460 and MCF7 cells, consistent with our
hypothesis that the thieno[2,3-b]pyridines act
as potentiators of topotecan.
To confirm the involvement of TDP1 block-
ade in potentiating topotecan, we used CRISPR/








































































































































































Fig. 2 The potentiating effect of DJ009, DJ016 and
DJ282 with topotecan (abbreviated as TPT in the figure).
The topotecan concentration is 12.5 nM for MCF7 and
25 nM for H460. IC50 values for the combination
treatments (by identification of the 50% value, dashed
line) are shown on each graph. Data are mean ± SE of
three independent experiments. DJ009 showed the
strongest synergistic effect as calculated using the Bliss
additivism model [48]. The average Bliss value (where
Bliss[ 1, indicates synergy) for the combination of the
thieno[2,3-b]pyridine compounds and topotecan were
44.2 ± 11.4, 31.8 ± 8.1 and 37.4 ± 8.0 for DJ009,
DJ016, and DJ282, respectively in MCF7 cells. The
combined treatment for H460 cells also showed a
synergistic effect with Bliss values of 60.9 ± 17.8,
31.1 ± 8.9 and 58.6 ± 14.8 for DJ009, DJ016 and
DJ282, respectively. These results clearly demonstrate a
strong synergistic effect between the three thieno[2,3-
b]pyridines and topotecan
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palindromic repeats/CRISPR associated protein
9) to knock out TDP1. We introduced frameshift
mutations in the TDP1 coding sequence using
gRNAs against TDP1 to generate TDP1 knockout
(KO) clones in MCF7 and H460 cancer cells.
Frameshift mutations in knockout cell lines
were validated by Sanger sequencing, and
complete TDP1 ablation was verified by
immunoblotting (see Supporting Information,
Figure S12). We then tested the sensitivity of
topotecan in the TDP1 KO clones (MCF7
KO_2.8 and H460 KO_1.3) and compared our
results with the wild-type cells (MCF7 and
H460). Our results showed that TDP1-deficient
H460 and MCF7 cells proliferated less when
exposed to topotecan (Fig. 3). The IC50 values
for topotecan were 25.2 ± 1.6 nM in wild-type
MCF7 cells and 10.5 ± 1.1 lM in TDP1 KO_2.8
MCF7 cells. Similarly, the IC50 values for
topotecan were 32.4 ± 1.8 nM in TDP1 KO_1.3
cells, and IC50 was not reached at 50 nM in
wild-type H460 cells. Our results showing that
cells lacking TDP1 have hypersensitivity to
topotecan are indicative that TDP1 is critical for
the repair of DNA damage (measured by
increased H2AX), which is consistent with pre-
vious studies [18, 19].
One of the curious findings in our cell pro-
liferation experiments was that different cell
lines have different sensitivity towards topote-
can on its own or in combination with DJ009.
We reasoned that TDP1 abundance may
influence the sensitivity of the cell lines to
topotecan tested in this study. To test this
hypothesis, we investigated the expression level
of TDP1 protein in the panel of cell lines.
Immunoblotting showed that TDP1 is expressed
in all the cell lines tested, although the level is
relatively low in the pancreatic cancer cell lines
MiaPaCa and PANC1, and lung cancer cell line
A549 (see Supporting Information, Figure S12).
We also computed Pearson correlation coeffi-
cients between the sensitivity of 358 diverse
cancer cell lines to topoisomerase I inhibitors
irinotecan/topotecan and their TDP1 mRNA
expression using data downloaded from the
Cancer Dependency Map portal (see Supporting
Information, Figure S13). By applying network
correlation analysis, we found that the correla-
tion between TDP1 mRNA expression and the
potency of topoisomerase I inhibitors is very
weak (median r = -0.3). This analysis suggests
that elevated TDP1 expression cannot predict
the sensitivity of cancer cells towards topoiso-
merase I inhibitors, an observation that is in
agreement with previous studies [80–82]. The
finding from the network correlation analysis is
also consistent with our experimental results
showing that the sensitivity to topotecan or the
combination effect of DJ009 and topotecan was
not correlated with the protein expression. For
example, SKBR3 showed similar TDP1 expres-
sion level to H460 cells (see Supporting Infor-
mation, Figure S12), but no significant
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Fig. 3 The effect of TDP1 KO on the antiproliferative
activity of topotecan (abbreviated as TPT in figure axis) as
compared to WT cells. TDP1 KO increases the sensitivity
of cells to topotecan, with the greatest effect observed in
H460 cells. Data are mean ± SE of three independent
experiments
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difference was observed in the treatment of
topotecan alone or in combination with DJ009
in the SKBR3 cell line (as opposed to H460,
which showed a significant potentiation effect)
(see Supporting Information, Figure S10).
Thieno[2,3-b]pyridines have many different
targets [35, 38, 69, 73, 76, 77], and off-target
toxicity is also commonly reported in cancer
drug candidates. We therefore exposed MCF7
and H460 KO clones to TDP1 inhibitors and
topotecan concomitantly to examine potential
off-target effects. Unexpectedly, all three inhi-
bitors tested also sensitized the TDP1 KO cells to
topotecan antiproliferative effects apart from
DJ016 in the MCF7 knockout KO_2.8 cell line
(Fig. 4), indicating that these compounds are
modulating other pathways that may con-
tribute to the observed potentiation effect of
topotecan. Previous studies have proposed that
TDP2 and poly(ADP-ribose)polymerase 1
(PARP1) may aid the repair of DNA strand
breaks caused by topoisomerase I inhibitors
[39, 40, 83]. To determine whether the
potentiation effects observed with the KO cell
lines were due to thieno[2,3-b]pyridines target-
ing TDP2, we tested the potentiation effect of
DJ009, DJ016 or DJ282 with topoisomerase II
inhibitor (doxorubicin). This is because TDP2
has been reported to be involved in the repair of
topoisomerase II inhibitor-induced damage
[84, 85]. However, our results showed that there
are no synergistic effects between DJ009/DJ016
and doxorubicin (see Supporting Information,
Figure S14). The only exception is DJ282 in
MCF7 cells. However, as DJ282 showed some
inhibitory effect towards MCF7 cell growth in
the absence of doxorubicin, the additional
reduced proliferation by DJ282 is not likely due
to enhancement of doxorubicin inhibition.
Hence, our data indicate that DJ009, DJ016 and
DJ282 can selectively enhance the efficacy of
topoisomerase I inhibitor topotecan but not
topoisomerase II inhibitor doxorubicin; i.e.,
thieno[2,3-b]pyridines are unlikely to target
TDP2. In contrast, we found that PARP1 inhi-
bitor olaparib can further sensitize the cancer
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Fig. 4 The dose response plots and corresponding bar
graphs with the IC50 values of the different potency of
each compound in combination with topotecan the WT
and the corresponding TDP1 knockout (KO) in
(a) MCF7 breast cancer cell line and b H460 lung cancer
cell line. The concentration of each TDP1 inhibitor was
430 nM for all the experiments. *p\ 0.05 and data are
mean ± SE of three independent experiments
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cells to topotecan (see Supporting Information,
Figure S15). Proliferation assay showed a
potentiating effect in MCF7 and H460 cells
treated with olaparib and topotecan. The syn-
ergistic interaction between olaparib, DJ009 and
topotecan was most notable in the H460 cell
line (see Supporting Information, Figure S15).
Although it is not clear whether our thieno[2,3-
b]pyridine compounds are directly targeting
PARP1 or its downstream/upstream path-
way(s) (in addition to targeting TDP1), our
results collectively showed that sensitivity to
topoisomerase I inhibitors is likely to be mod-
ulated by multiple DNA repair enzymes,
including TDP1 and PARP1.
DISCUSSION
Topoisomerase I inhibitors such as topotecan
and irinotecan are clinically used chemothera-
peutic agents that have shown to be highly
effective in the treatments of a number of can-
cers including ovarian cancer, colorectal cancer,
small cell lung cancer and cervical cancer. The
development of resistance against topoiso-
merase I inhibitors is a major obstacle for the
successful treatments of these cancers. Exten-
sive work has been conducted in the last two
decades to develop chemosensitizers for topoi-
somerase I poisons to help delay or reverse their
chemoresistance. Several DNA repair pathways,
including (but not limited to) those mediated
by TDP1, TDP2 and PARP1, have been proposed
to be involved in repairing topoisomerase
I-mediated DNA damage, and hence they are
potential inhibition targets to improve the
efficiency of topoisomerase I poisons. In par-
ticular, TDP1 is a potentially important target as
it is directly involved in the release of the stalled
topoisomerase I-DNA cleavage complexes that
is caused by topoisomerase I inhibitors. Hence,
in this study, we set out to validate TDP1 as an
inhibition target for the development of new
chemosensitizers against topoisomerase I
poisons.
By using thieno[2,3-b]pyridines, a class of
compounds that we have shown to be highly
potent against TDP1, as model compounds, we
showed that inhibition of TDP1 can restore
sensitivity to topoisomerase I inhibitors such as
topotecan in some cancer cell lines. This is
supported by the CRISPR/Cas9 knockout cell
experiments. Hence, our results validate TDP1
as a target for the development of new
chemosensitizers against topoisomerase I poi-
sons. However, our results also revealed a more
complex picture. Firstly, we found that sensi-
tivity towards topotecan and the combination
of topotecan and thieno[2,3-b]pyridines differs
between different cell lines, and is not neces-
sarily linked to the expression of TDP1. Sec-
ondly, we found that thieno[2,3-b]pyridines
also induced a potentiation effect of topotecan
in TDP1 knockout cells, showing that our
thieno[2,3-b]pyridines are not specific to TDP1.
These implied that the sensitivity towards
topoisomerase I inhibitors that we observed is
likely being modulated by multiple pathways,
of which TDP1 is only one. Our results using
topoisomerase II poisons and PARP1 inhibitors
showed that pathway(s) modulated by PARP1
are likely candidate(s), although it is also highly
possible that other redundant and partially
overlapping pathways may be involved in the
DNA repair process.
Our work also exposes challenges and
opportunities in the development of
chemosensitizers for topoisomerase I inhibitors.
Firstly, our results help establish TDP1 as a
desirable inhibition target for the development
of chemosensitizers against topoisomerase I
poisons. It also opens the possibility of targeting
multiple DNA repair pathways to further
increase the sensitivity towards topoisomerase I
inhibitors. This is an area that warrants further
research, as it may significantly improve clinical
outcomes and maximize the potential for
topoisomerase I inhibitor-based treatments. It is
important to note, however, that thieno[2,3-
b]pyridines only showed synergistic effects with
topotecan in some cell lines. Further work is
therefore needed to fully understand the rea-
sons behind this observation. For example, it is
possible that the intrinsic responsiveness and/or
activity of DNA repair pathways between cell
lines are different. It is also possible that there
may exist other DNA repair pathway(s) (that do
not respond to thieno[2,3-b]pyridines) that are
more dominant in some cancer cells. Secondly,
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our results showed that a better biomarker (or
set of biomarkers) than TDP1 is needed to aid
the prediction of sensitivity towards topoiso-
merase I inhibitors. The elucidation of the
complete network of pathways that is involved
in the repair of DNA damage caused by topoi-
somerase I inhibitors would be very helpful for
biomarker identification. A more complete
understanding of the intricate human DNA
damage response and repair network would also
help in the identification of further inhibition
targets for the development of new chemosen-
sitizers. One possible strategy to map the pos-
sible DNA repair pathways that are involved in
repairing damage caused by topoisomerase I
inhibitors is to design photocrosslinking
chemical probes based on our thieno[2,3-
b]pyridines. This may enable the identification
of proteins and enzymes (other than TDP1) that
interact with our thieno[2,3-b]pyridine
compounds.
CONCLUSIONS
Overall, by using thieno[2,3-b]pyridines, a class
of TDP1 inhibitors that we had previously
developed, we showed that the inhibition of
TDP1 can restore sensitivity to topotecan in
some cell lines. However, experiments with
TDP1 knockout cells showed that thieno[2,3-
b]pyridines are not specific to TDP1, as we
found that thieno[2,3-b]pyridines could also
potentiate the effect of topoisomerase I poisons
in TDP1 knockout cells. To further investigate
this redundancy, we probed whether TDP2 and
PARP1 are involved in repairing topoisomerase I
inhibitor-induced DNA damage. We found that
PARP1 inhibitor olaparib can further sensitize
the effect of topoisomerase I poisons in the
presence of thieno[2,3-b]pyridines, indicating
that the PARP1 pathway is complementary to
the TDP1 pathway in repairing damage cause by
topoisomerase I inhibitors. Our work therefore
opens up the avenue of targeting and inhibiting
enzymes from multiple DNA repair pathways
simultaneously to increase the sensitivity to
topoisomerase I inhibitors.
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Euphemia Leung, Jóhannes Reynisson, Ivanhoe
K. H. Leung; Methodology: Euphemia Leung,
Jinal Patel, Jennifer A. Hollywood, Ayesha Zafar,
Petr Tomek, David Barker, Lisa I. Pilkington,
Michelle van Rensburg, Ries J. Langley, Nuala A.
Helsby, Christopher J. Squire, Bruce C. Baguley,
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William A. Denny, Jóhannes Reynisson and
Ivanhoe K. H. Leung have nothing to declare.
Compliance with Ethics Guidelines. Ethical
committee approval was not required as no
human, animal or human embryonic stem cells
were used in the study. Our gene editing
experiments were operated under the New
Zealand HSNO approval (GM005-UA0022). The
use of genetically modified E. coli for recombi-
nant protein production was operated under
the University of Auckland-wide approval
(APP202708) by the New Zealand Environmen-
tal Protection Authority.
Data Availability. All data generated or
analyzed during this study are included in this
published article/as supplementary information
files.
Open Access. This article is licensed under a
Creative Commons Attribution-NonCommer-
cial 4.0 International License, which permits
any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium
or format, as long as you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons licence, and
indicate if changes were made. The images or
other third party material in this article are
included in the article’s Creative Commons
licence, unless indicated otherwise in a credit
line to the material. If material is not included
in the article’s Creative Commons licence and
your intended use is not permitted by statutory
regulation or exceeds the permitted use, you
will need to obtain permission directly from the




1. Guestini F, McNamara KM, Sasano H. The use of
chemosensitizers to enhance the response to con-
ventional therapy in triple-negative breast cancer
patients. Breast Cancer Manag. 2018;6:127–31.
2. Michod D, Widmann C. DNA-damage sensitizers:
potential new therapeutical tools to improve
chemotherapy. Crit Rev Oncol Hematol. 2007;63:
160–71.
3. Martino E, Della Volpe S, Terribile E, Benetti E,
Sakaj M, Centamore A, Sala A, Collina S. The long
story of camptothecin: from traditional medicine to
drugs. Bioorg Med Chem Lett. 2017;27:701–7.
4. Venditto VJ, Simanek EE. Cancer therapies utilizing
the camptothecins: a review of in vivo literature.
Mol Pharm. 2010;7:307–49.
5. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin:
current perspectives. Bioorg Med Chem. 2004;12:
1585–604.
6. Capranico G, Marinello J, Chillemi G. Type I DNA
topoisomerases. J Med Chem. 2017;60:2169–92.
7. Hartman Chen S, Chan N-L, Hsieh T-S. New
mechanistic and functional insights into DNA
topoisomerases. Annu Rev Biochem. 2013;82:
139–70.
8. Liu LR, Desai SD, Li T-K, Mao Y, Sun M, Sim S-P.
Mechanism of action of camptothecin. Ann N Y
Acad Sci. 2000;922:1–10.
9. Hertzberg RP, Caranfa MJ, Hecht SM. On the
mechanism of topoisomerase I inhibition by
camptothecin: evidence for binding to an enzyme-
DNA complex. Biochemistry. 1989;28:4629–38.
Oncol Ther
10. Nickoloff JA, Jones D, Lee S-H, Williamson EA,
Hromas R. Drugging the cancers addicted to DNA
repair. J Natl Cancer Inst. 2017;109:djx059.
11. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ.
DNA repair and resistance to topoisomerase I inhi-
bitors: mechanisms, biomarkers and therapeutic
targets. Curr Med Chem. 2012;19:3874–85.
12. Beretta GL, Gatti L, Perego P, Zaffaroni N. Camp-
tothecin resistance in cancer: insights into the
molecular mechanisms of a DNA-damaging drug.
Curr Med Chem. 2013;20:1541–65.
13. Heo J, Li J, Summerlin M, Hays A, Katyal S,
McKinnon PJ, Nitiss KC, Nitiss JL, Hanakahi LA.
TDP1 promotes assembly of non-homologous end
joining protein complexes on DNA. DNA Repair.
2015;30:28–37.
14. Interthal H, Pouliot JJ, Champoux JJ. The tyrosyl-
DNA phosphodiesterase Tdp1 is a member of the
phospholipase D superfamily. Proc Natl Acad Sci
USA. 2001;98:12009–14.
15. Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast
gene for a Tyr-DNA phosphodiesterase that repairs
topoisomerase I complexes. Science. 1999;286:
552–5.
16. Jakobsen A-K, Lauridsen KL, Samuel EB, Proszek J,
Knudsen BR, Hager H, Stougaard M. Correlation
between topoisomerase I and tyrosyl-DNA phos-
phodiesterase 1 activities in non-small cell lung
cancer tissue. Exp Mol Pathol. 2015;99:56–64.
17. Barthelmes HU, Habermeyer M, Christensen MO,
Mielke C, Interthal H, Pouliot JJ, Boege F, Marko D.
TDP1 overexpression in human cells counteracts
DNA damage mediated by topoisomerases I and II.
J Biol Chem. 2004;279:55618–25.
18. Murai J, Huang S-YN, Das BB, Dexheimer TS,
Takeda S, Pommier Y. Tyrosyl-DNA phosphodi-
esterase 1 (TDP1) repairs DNA damage induced by
topoisomerases I and II and base alkylation in ver-
tebrate cells. J Biol Chem. 2012;287:12848–57.
19. Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J,
Leppard JB, Champoux JJ. SCAN1 mutant Tdp1
accumulates the enzyme–DNA intermediate and
causes camptothecin hypersensitivity. EMBO J.
2005;24:2224–33.
20. Salomatina OV, Popadyuk II, Zakharenko AL,
Zakharova OD, Chepanova AA, Dyrkheeva NS,
Komarova NI, Reynisson J, Anarbaev RO,
Salakhutdinov NF, Lavrik OI, Volcho KP. Deoxy-
cholic acid as a molecular scaffold for tyrosyl-DNA
phosphodiesterase 1 inhibition: a synthesis, struc-
ture–activity relationship and molecular modeling
study. Steroids. 2021;165:108771.
21. Gladkova ED, Nechepurenko IV, Bredikhin RA,
Chepanova AA, Zakharenko AL, Luzina OA, Ilina
ES, Dyrkheeva NS, Mamontova EM, Anarbaev RO,
Reynisson J, Volcho KP, Salakhutdinov NF, Lavrik
OI. The first berberine-based inhibitors of tyrosyl-
DNA phosphodiesterase 1 (Tdp1), an important
DNA repair enzyme. Int J Mol Sci. 2020;21:7162.
22. Il’ina IV, Dyrkheeva NS, Zakharenko AL, Sidorenko
AYu, Li-Zhulanov NS, Korchagina DV, Chand R,
Ayine-Tora DM, Chepanova AA, Zakharova OD,
Ilina ES, Reynisson J, Malakhova AA, Medvedev SP,
Zakian SM, Volcho KP, Salakhutdinov NF, Lavrik
OI. Design, synthesis, and biological investigation
of novel classes of 3-carene-derived potent inhibi-
tors of TDP1. Molecules. 2020;25:3496.
23. Mamontova EM, Zakharenko AL, Zakharova OD,
Dyrkheeva NS, Volcho KP, Reynisson J, Arabshahi
HJ, Salakhutdinov NF, Lavrik OI. Identification of
novel inhibitors for the tyrosyl-DNA-phosphodi-
esterase 1 (Tdp1) mutant SCAN1 using virtual
screening. Bioorg Med Chem. 2020;28:115234.
24. Khomenko TM, Zakharenko AL, Chepanova AA,
Ilina ES, Zakharova OD, Kaledin VI, Nikolin VP,
Popova NA, Korchagina DV, Reynisson J, Chand R,
Ayine-Tora DM, Patel J, Leung IKH, Volcho KP,
Salakhutdinov NF, Lavrik OI. Promising new inhi-
bitors of tyrosyl-DNA phosphodiesterase I (Tdp 1)
combining 4-arylcoumarin and monoterpenoid
moieties as components of complex antitumor
therapy. Int J Mol Sci. 2020;21:126.
25. Chepanova AA, Li-Zhulanov NS, Sukhikh AS, Zafar
A, Reynisson J, Zakharenko AL, Zakharova OD,
Korchagina DV, Volcho KP, Salakhutdinov NF,
Lavrik OI. Effective inhibitors of tyrosyl-DNA
phosphodiesterase 1 based on monoterpenoids as
potential agents for antitumor therapy. Russ J
Bioorg Chem. 2019;45:647–55.
26. Mozhaitsev E, Suslov E, Demidova Y, Korchagina D,
Volcho K, Zakharenko A, Vasil’eva I, Kupryushkin
M, Chepanova A, Ayine-Tora DM, Reynisson J,
Salakhutdinov N, Lavrik O. The development of
tyrosyl-DNA phosphodyesterase 1 (TDP1) inhibitors
based on the amines combining aromatic/
heteroaromatic and monoterpenoid moieties. Lett
Drug Des Discov. 2019;16:597–605.
27. Chepanova AA, Mozhaitsev ES, Munkuev AA, Sus-
lov EV, Korchagina DV, Zakharova OD, Zakharenko
AL, Patel J, Ayine-Tora DM, Reynisson J, Leung IKH,
Volcho KP, Salakhutdinov NF, Lavrik OI. The
development of tyrosyl-DNA phosphodiesterase 1
inhibitors. Combination of monoterpene and
adamantine moieties via amide or thioamides
bridges. Appl Sci. 2019;9:2767.
28. Filimonov AS, Chepanova AA, Luzina OA, Zakhar-
enko AL, Zakharova OD, Ilina ES, Dyrkheeva NS,
Oncol Ther
Kuprushkin MS, Kolotaev AV, Khachatryan DS,
Patel J, Leung IKH, Chand R, Ayine-Tora DM,
Reynisson J, Volcho KP, Salakhutdinov NF, Lavrik
OI. New hydrazinothiazole derivatives of usnic acid
as potent Tdp1 inhibitors. Molecules. 2019;24:
3711.
29. Mozhaitsev ES, Zakharenko AL, Suslov EV, Kor-
chagina DV, Zakharova OD, Vasil’eva IA, Chep-
anova AA, Black E, Patel J, Chand R, Reynisson J,
Leung IKH, Volcho KP, Salakhutdinov NF, Lavrik
OI. Novel inhibitors of DNA repair enzyme TDP1
combining monoterpenoid and adamantane frag-
ments. Anti-Cancer Agents Med Chem. 2019;19:
463–72.
30. Zakharova O, Luzina O, Zakharenko A, Sokolov D,
Filimonov A, Dyrkheeva N, Chepanova A, Ilina E,
Ilyina A, Klabenkova K, Chelobanov B, Stetsenko D,
Zafar A, Eurtivong C, Reynisson J, Volcho K,
Salakhutdinov N, Lavrik O. Synthesis and evalua-
tion of aryliden- and hetarylidenfuranone deriva-
tives of usnic acid as highly potent Tdp1 inhibitors.
Bioorg Med Chem. 2018;26:4470–80.
31. Zakharenko AL, Luzina OA, Sokolov DN, Kaledin
VI, Nikolin VP, Popova NA, Patel J, Zakharova OD,
Chepanova AA, Zafar A, Reynisson J, Leung E,
Leung IKH, Volcho KP, Salakhutdinov NF, Lavrik
OI. Novel tyrosyl-DNA phosphodiesterase 1 inhibi-
tors enhance the therapeutic impact of topotecan
on in vivo tumor models. Eur J Med Chem.
2019;161:581–93.
32. Li-Zhulanov NS, Zakharenko AL, Chepanova AA,
Patel J, Zafar A, Volcho KP, Salakhutdinov NF,
Reynisson J, Leung IKH, Lavrik OI. A novel class of
tyrosyl-DNA phosphodiesterase 1 inhibitors that
contains the octahydro-2H-chromen-4-ol scaffold.
Molecules. 2018;23:2468.
33. Ponomarev KY, Suslov EV, Zakharenko AL,
Zakharova OD, Rogachev AD, Korchagina DV, Zafar
A, Reynisson J, Nefedov AA, Volcho KP, Salakhut-
dinov NF, Lavrik OI. Aminoadamantanes contain-
ing monoterpene-derived fragments as potent
tyrosyl-DNA phosphodiesterase 1 inhibitors. Bioorg
Chem. 2018;76:392–9.
34. Salomatina OV, Popadyuk II, Zakharenko AL,
Zakharova OD, Fadeev DS, Komarova NI, Reynisson
J, Arabshahi HJ, Chand R, Volcho KP, Salakhutdi-
nov NF, Lavrik OI. Novel semisynthetic derivatives
of bile acids as effective tyrosyl-DNA phosphodi-
esterase 1 inhibitors. Molecules. 2018;23:679.
35. Zafar A, Sari S, Leung E, Pilkington LI, van Rensburg
M, Barker D, Reynisson J. GPCR modulation of
thieno[2,3-b]pyridine anti-proliferative agents.
Molecules. 2017;22:2254.
36. Khomenko T, Zakharenko A, Odarchenko T, Arab-
shahi HJ, Sannikova V, Zakharova O, Korchagina D,
Reynisson J, Volcho K, Salakhutdinov N, Lavrik O.
New inhibitors of tyrosyl-DNA phosphodiesterase I
(Tdp 1) combining 7-hydroxycoumarin and
monoterpenoid moieties. Bioorg Med Chem.
2016;24:5573–81.
37. Zakharenko A, Khomenko T, Zhukova S, Koval O,
Zakharova O, Anarbaev R, Lebedeva N, Korchagina
D, Komarova N, Vasiliev V, Reynisson J, Volcho K,
Salakhutdinov N, Lavrik O. Synthesis and biological
evaluation of novel tyrosyl-DNA phosphodiesterase
1 inhibitors with a benzopentathiepine moiety.
Bioorg Med Chem. 2015;23:2044–52.
38. Arabshahi HJ, van Rensburg M, Pilkington LI, Jeon
CY, Song M, Gridel L-M, Leung E, Barker D, Vuica-
Ross M, Volcho KP, Zakharenko AL, Lavrik OI,
Reynisson J. A synthesis, in silico, in vitro and in vivo
study of thieno[2,3-b]pyridine anticancer ana-
logues. Med Chem Commun. 2015;6:1987–97.
39. Fam HK, Walton C, Mitra SA, Chowdhury M,
Osborne N, Choi K, Sun G, Wong PCW, O’Sullivan
MJ, Turashvili G, Aparicio S, Triche TJ, Bond M,
Pallen CJ, Boerkoel CF. TDP1 and PARP1 deficiency
are cytotoxic to rhabdomyosarcoma cells. Mol
Cancer Res. 2013;11:1179–92.
40. Zeng Z, Sharma A, Ju L, Murai J, Umans L, Vermeire
L, Pommier Y, Takeda S, Huylebroeck D, Caldecott
KW, El-Khamisy SF. TDP2 promotes repair of
topoisomerase I-mediated DNA damage in the
absence of TDP1. Nucleic Acids Res. 2012;40:
8371–80.
41. Deng C, Brown JA, You D, Brown JM. Multiple
endonucleases function to repair covalent topoiso-
merase I complexes in Saccharomyces cerevisiae.
Genetics. 2005;170:591–600.
42. Vance JR, Wilson TE. Yeast Tdp1 and Rad1-Rad10
function as redundant pathways for repairing Top1
replicative damage. Proc Natl Acad Sci USA.
2002;99:13669–74.
43. Liu C, Pouliot JJ, Nash HA. Repair of topoisomerase
I covalent complexes in the absence of the tyrosyl-
DNA phosphodiesterase Tdp1. Proc Natl Acad Sci
USA. 2002;99:14970–5.
44. Leung EY, Kim JE, Askarian-Amiri M, Rewcastle
GW, Finlay GJ, Baguley BC. Relationships between
signaling pathway usage and sensitivity to a path-
way inhibitor: examination of trametinib responses
in cultured breast cancer lines. PLoS ONE. 2014;9:
e105792.
45. Leung E, Kannan N, Krissansen GW, Findlay MP,
Baguley BC. MCF7 breast cancer cells selected for
tamoxifen resistance acquire new phenotypes
Oncol Ther
differing in DNA content, phospho-HER2 and PAX2
expression, and rapamycin sensitivity. Cancer Biol
Ther. 2010;9:717–24.
46. Li J, Summerlin M, Nitiss KC, Nitiss JL, Hanakahi
LA. TDP1 is required for efficient non-homologous
end joining in human cells. DNA Repair. 2017;60:
40–9.
47. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA,
Zhang F. Genome engineering using the CRISPR-
Cas9 system. Nat Protoc. 2013;8:2281–307.
48. Berenbaum MC. Criteria for analyzing interactions
between biologically active agents. Adv Cancer Res.
1981;35:269–335.
49. Lountos GT, Zhao XZ, Kiselev E, Tropea JE, Needle
D, Pommier Y, Burke TR, Waugh DS. Identification
of a ligand binding hot spot and structural motifs
replicating aspects of tyrosyl-DNA phosphodi-
esterase I (TDP1) phosphoryl recognition by crys-
tallographic fragment cocktail screening. Nucleic
Acids Res. 2019;47:10134–50.
50. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat
TN, Weissig H, Shindyalov IN, Bourne PE. The
protein data bank. Nucleic Acids Res. 2000;28:
235–42.
51. Berman H, Henrick K, Nakamura H. Announcing
the worldwide protein data bank. Nat Struct Biol.
2003;10:980.
52. Scigress Ultra V, F.J 2.6. (EU 3.1.7); Fujitsu Limited:
2008–2016.
53. Allinger NL. Conformational analysis. 130. MM2. A
hydrocarbon force field utilizing V1 and V2 tor-
sional terms. J Am Chem Soc. 1977;99:8127–34.
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